[go: up one dir, main page]

SV2002000082A - Profarmacos mutuos de amlodipino y atorvastatina ref.pc10268 artr/bb - Google Patents

Profarmacos mutuos de amlodipino y atorvastatina ref.pc10268 artr/bb

Info

Publication number
SV2002000082A
SV2002000082A SV2000000082A SV2000000082A SV2002000082A SV 2002000082 A SV2002000082 A SV 2002000082A SV 2000000082 A SV2000000082 A SV 2000000082A SV 2000000082 A SV2000000082 A SV 2000000082A SV 2002000082 A SV2002000082 A SV 2002000082A
Authority
SV
El Salvador
Prior art keywords
amlodipino
atorvastatin
mutual
propharmaces
artr
Prior art date
Application number
SV2000000082A
Other languages
English (en)
Inventor
George Chang
Ernest Seiichi Hamanaka
John Lawrence Lamattina
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of SV2002000082A publication Critical patent/SV2002000082A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)

Abstract

ESTA INVENCION SE REFIERE A LOS PROFARMACOS MUTUOS DE AMLODIPINO Y ATORVASTATINA Y A LAS COMPOSICIONES FARMACEUTICAS DE LOS MISMOS. ESTA INVENCION TAMBIEN SE REFIERE A LOS PROCEDIMIENTOS PARA TRATAR LA ANGINA DE PECHO, LA ATEROSCLEROSIS Y LA HIPERTENSION Y LA HIPERLIPIDEMIA EN UN MAMIFERO MEDIANTE EL USO DE ESTOS PROFARMACOS Y COMPOSICIONES. ESTA INVENCION TAMBIEN SE REFIEREA LOS PROCEDIMIENTOS PARA TRATAR ELRIESGO CARDIACO EN UN MAMIFERO INCLUYENDO HUMANOS, QUE PRESENTA SINTOMAS DE RIESGO CARDIACO MEDIANTE LA ADMINISTRACION DE ESTOS PROFARMACOS Y COMPOSICIONES.
SV2000000082A 1999-05-27 2000-05-25 Profarmacos mutuos de amlodipino y atorvastatina ref.pc10268 artr/bb SV2002000082A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US13660899P 1999-05-27 1999-05-27

Publications (1)

Publication Number Publication Date
SV2002000082A true SV2002000082A (es) 2002-02-05

Family

ID=22473579

Family Applications (1)

Application Number Title Priority Date Filing Date
SV2000000082A SV2002000082A (es) 1999-05-27 2000-05-25 Profarmacos mutuos de amlodipino y atorvastatina ref.pc10268 artr/bb

Country Status (41)

Country Link
US (1) US6486182B1 (es)
EP (1) EP1180102B9 (es)
JP (1) JP2003500487A (es)
KR (1) KR20020012247A (es)
CN (1) CN1352640A (es)
AP (1) AP2001002345A0 (es)
AR (1) AR022344A1 (es)
AT (1) ATE268764T1 (es)
AU (1) AU3313900A (es)
BG (1) BG106149A (es)
BR (1) BR0011006A (es)
CA (1) CA2375372C (es)
CO (1) CO5170457A1 (es)
CZ (1) CZ20014229A3 (es)
DE (1) DE60011424T2 (es)
DK (1) DK1180102T3 (es)
DZ (1) DZ3048A1 (es)
EA (1) EA200101130A1 (es)
EE (1) EE200100631A (es)
ES (1) ES2220426T3 (es)
GT (1) GT200000078A (es)
HK (1) HK1046282A1 (es)
HN (1) HN2000000075A (es)
HR (1) HRP20010856A2 (es)
HU (1) HUP0201433A2 (es)
IL (1) IL145947A0 (es)
IS (1) IS6135A (es)
MA (1) MA26736A1 (es)
MX (1) MXPA01012125A (es)
NO (1) NO20015756L (es)
OA (1) OA11950A (es)
PA (1) PA8495701A1 (es)
PE (1) PE20010169A1 (es)
PL (1) PL353483A1 (es)
PT (1) PT1180102E (es)
SK (1) SK16792001A3 (es)
SV (1) SV2002000082A (es)
TN (1) TNSN00113A1 (es)
TR (1) TR200103391T2 (es)
WO (1) WO2000073298A1 (es)
ZA (1) ZA200109691B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GT199800127A (es) * 1997-08-29 2000-02-01 Combinaciones terapeuticas.
US6737430B2 (en) 2000-11-09 2004-05-18 Pfizer, Inc. Mutual prodrug of amlodipine and atorvastatin
GB0027410D0 (en) * 2000-11-09 2000-12-27 Pfizer Ltd Mutual prodrug of amlodipine and atorvastatin
US7186855B2 (en) 2001-06-11 2007-03-06 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US6818787B2 (en) 2001-06-11 2004-11-16 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US8048917B2 (en) 2005-04-06 2011-11-01 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US7232924B2 (en) 2001-06-11 2007-06-19 Xenoport, Inc. Methods for synthesis of acyloxyalkyl derivatives of GABA analogs
KR20070108282A (ko) 2001-06-11 2007-11-08 제노포트 인코포레이티드 감소된 독성을 가진 ｇａｂａ 유사체 프로드러그의 구강투여용 투여 형태물
DE10140421A1 (de) * 2001-08-17 2003-03-06 Bayer Ag Neue Kombination
US7670612B2 (en) 2002-04-10 2010-03-02 Innercap Technologies, Inc. Multi-phase, multi-compartment capsular delivery apparatus and methods for using same
US7071210B2 (en) * 2002-07-02 2006-07-04 Pfizer Inc. CETP inhibitors in combination with antihypertensive agents and uses thereof
US20040053842A1 (en) * 2002-07-02 2004-03-18 Pfizer Inc. Methods of treatment with CETP inhibitors and antihypertensive agents
AU2005301970B2 (en) 2004-11-04 2011-06-02 Arbor Pharmaceuticals, Llc Gabapentin prodrug sustained release oral dosage forms
WO2007016306A2 (en) * 2005-08-01 2007-02-08 Psivida Inc. HMGCoA REDUCTASE INHIBITOR CODRUGS AND USES THEREOF
AR057882A1 (es) 2005-11-09 2007-12-26 Novartis Ag Compuestos de accion doble de bloqueadores del receptor de angiotensina e inhibidores de endopeptidasa neutra
US8354116B2 (en) * 2007-06-18 2013-01-15 Biochemics, Inc. Bifunctional synthetic molecules
US8371336B2 (en) 2007-10-10 2013-02-12 Eagle Industry Co., Ltd. Accumulator

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK161312C (da) 1982-03-11 1991-12-09 Pfizer Analogifremgangsmaade til fremstilling af 2-aminoalkoxymethyl-4-phenyl-6-methyl-1,4-dihydropyridin-3,5-dicarboxylsyreestere eller syreadditionssalte deraf samt phthalimidoderivater til anvendelse som udgangsmateriale ved fremgangsmaaden
GB8608335D0 (en) 1986-04-04 1986-05-08 Pfizer Ltd Pharmaceutically acceptable salts
US4681893A (en) 1986-05-30 1987-07-21 Warner-Lambert Company Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis
FI94339C (fi) 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
US5155120A (en) 1991-01-14 1992-10-13 Pfizer Inc Method for treating congestive heart failure
GT199800127A (es) * 1997-08-29 2000-02-01 Combinaciones terapeuticas.

Also Published As

Publication number Publication date
CO5170457A1 (es) 2002-06-27
CZ20014229A3 (cs) 2003-01-15
WO2000073298A1 (en) 2000-12-07
HUP0201433A2 (en) 2002-08-28
TNSN00113A1 (fr) 2005-11-10
PL353483A1 (en) 2003-11-17
DE60011424D1 (de) 2004-07-15
MXPA01012125A (es) 2002-06-04
ATE268764T1 (de) 2004-06-15
HN2000000075A (es) 2001-02-02
BR0011006A (pt) 2002-02-19
PT1180102E (pt) 2004-08-31
TR200103391T2 (tr) 2002-04-22
EA200101130A1 (ru) 2002-04-25
ZA200109691B (en) 2002-11-26
JP2003500487A (ja) 2003-01-07
NO20015756L (no) 2002-01-24
CN1352640A (zh) 2002-06-05
US6486182B1 (en) 2002-11-26
DK1180102T3 (da) 2004-09-06
CA2375372A1 (en) 2000-12-07
IS6135A (is) 2001-10-30
DZ3048A1 (fr) 2004-03-27
IL145947A0 (en) 2002-07-25
AU3313900A (en) 2000-12-18
AP2001002345A0 (en) 2001-12-31
GT200000078A (es) 2001-11-16
EP1180102A1 (en) 2002-02-20
CA2375372C (en) 2007-01-09
OA11950A (en) 2006-04-13
EP1180102B9 (en) 2005-03-02
AR022344A1 (es) 2002-09-04
HRP20010856A2 (en) 2002-12-31
DE60011424T2 (de) 2005-08-25
HK1046282A1 (zh) 2003-01-03
KR20020012247A (ko) 2002-02-15
EE200100631A (et) 2003-02-17
NO20015756D0 (no) 2001-11-26
BG106149A (en) 2002-05-31
ES2220426T3 (es) 2004-12-16
PA8495701A1 (es) 2001-12-14
EP1180102B1 (en) 2004-06-09
SK16792001A3 (sk) 2003-03-04
MA26736A1 (fr) 2004-12-20
PE20010169A1 (es) 2001-02-10

Similar Documents

Publication Publication Date Title
SV2002000082A (es) Profarmacos mutuos de amlodipino y atorvastatina ref.pc10268 artr/bb
HN2002000154A (es) Azaindoles
PA8462401A1 (es) Derivados de la tienopirimidina y de la tienopiridina utiles como agentes anticancerigenos
BR9812753A (pt) Combinação farmacêutica, uso da mesma, processo para tratamento de uma doença inflamatória, e, composição farmacêutica
CY1120313T1 (el) Φαρμακευτικη συνθεση για δερματικη χρηση για να θεραπευεται ψωριαση που περιλαμβανει βιταμινη d και κορτικοστεοειδες
GT199800134A (es) Terapia de combinacion.
PT1259512E (pt) Compostos de pteridin para o tratamento da psoriase
TR200101103T2 (tr) CGMP PDE-İnhibitörü içeren kontrollu serbest bırakılan farmasötik formülasyonlar
ES2178298T3 (es) Compuestos anti-inflamatorios.
BR0100046A (pt) Copolìmeros reticulados solúveis em água ou intumescìveis em água
GT199800158AA (es) Agonistas de prostaglandinas y su uso para tratar trastornos oseos
CL2009001279A1 (es) Compuestos derivados de nociceptina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del dolor (sol. divisional 2103-03).
BR9811556A (pt) Terapia de combinação compreendendo atorvastatina e um agente anti-hipertensivo
GT199700009AA (es) Terapia combinada para la osteoporosis
ES2191320T3 (es) Derivados de piperazina y su uso como agentes anti-inflamatorios.
PA8452701A1 (es) Agonistas de prostaglandinas
ECSP055701A (es) Nuevos derivados de pirimidinamida y el uso de los mismos
HN2000000050A (es) Sal mutua de amlodipino y atorvastatina
SE0101932D0 (sv) Pharmaceutical combinations
SE9901077D0 (sv) Novel use
BR0213181A (pt) Combinações de inibidor de cox-2
BR0010983A (pt) Preparações para a aplicação de agentes antiinflamatórios
SE9801494D0 (sv) Novel use
MX9300558A (es) Nueva sulfonilurea, procedimiento para su preparacion y formulado farmaceutico que la contiene.
MX9403032A (es) Quinolil-dihidropiridinas condensadas, procedimiento para su fabricacion ysu uso en medicamentos.

Legal Events

Date Code Title Description
FD Lapse